Advanced Search

Display
per page
  Report Title Date Provider Type Pgs Price

Aldeyra Therapeutics Inc: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis.

This report is essential reading for any serious investor, providing comprehensive financial information on a company's perfo...

28 Mar 2015 Reuters Investment Profile 12 $20.00

Thomson Reuters Stock Report - ALDEYRA THERAPEUTICS INC (ALDX-O)

StockReports+ gathers Thomson Reuters independent research, ratings and market data into a single report that optimizes the i...

01 Apr 2015 Thomson Reuters Stock Report 10 $25.00

ALDEXA THERAPEUTICS INC (ALDX) 12-months forecast

"www.pechala.com, the world's largest market forecasting firm with subscribers in 83 different countries provide forecasts of...

30 Mar 2015 Pechala's Reports 1 $15.00

ALDEXA THERAPEUTICS INC (ALDX) - REPORT FOR ACTIVE TRADERS

"www.pechala.com, the world's largest market forecasting firm with subscribers in 83 different countries provide forecasts of...

28 Mar 2015 Pechala's Reports 1 $25.00

ValuEngine Industry Report for Medical-drugs(ALDX)

Advanced academic research that brings you superior investment strategies in an actionable format. Industry Analysis Report, ...

26 Mar 2015 ValuEngine, Inc. 10 $49.00

ALDX: 4Q14: Overall uneventful but 2015 could be transformative as two key clinical results become available

This morning, ALDX reported 4Q14 financial results with a net loss of ($2.2MM), overall in-line with the estimates of Laidlaw...

19 Mar 2015 Laidlaw & Company 7 $25.00

ALDX: NS2 in SLS Phase II study started and the non-infectious anterior uveitis Phase II study to come likely in 2Q15

This morning, ALDX announced the commencement of the NS2 in Sjogren-Larsson Syndrome (SLS) Phase II study, and also indicated...

17 Mar 2015 Laidlaw & Company 7 $25.00

ALDX: NS2 clinical developments on SLS and non-infectious anterior uveitis remain on-track

This morning, ALDX provided an update on the clinical developments of NS2 indicating that the overall progress remains on tra...

02 Mar 2015 Laidlaw & Company 7 $25.00

ALDX: Novel aldehyde trapping approach could potentially afford new treatment modality in multiple diseases; initiation with a Buy rating and a 12-month price target of $30

We are initiating coverage of Aldeyra Therapeutics with a Buy rating and a $30 12-month price target. ALDX affords a novel al...

26 Jan 2015 Laidlaw & Company 31 $75.00

ALDX.OQ - Event Transcript of Aldeyra Therapeutics Inc conference call, Nov. 10, 2014 / 8:30AM ET

Edited Event Transcript of ALDX.OQ conference call, Nov. 10, 2014 / 8:30AM ET Boston, Nov 28, 2014 (Thomson StreetEvent...

10 Nov 2014 Thomson Reuters StreetEvents 9 $75.00